Bölüm notları
Drs Juloori and Carbone explore how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform first-line regimen selection for patients with driver-negative metastatic NSCLC.
Web sitesi: audioboom.com

